Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWAO33)

• Drug Name: SAR446159 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMWAO33

Molecule-Related Drug Atlas

Drug(s) Targeting Synuclein alpha (SNCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7935	DME1YMX	Parkinson disease	8A00.0	Phase 2	[2]
BIIB054	DMZO2SY	Parkinson disease	8A00.0	Phase 2	[3]
PRX002	DMKTP8E	Parkinson disease	8A00.0	Phase 2	[4]
TAK-341	DM6D30Q	Multiple system atrophy	8D87.0	Phase 2	[5]
MEDI1341	DMQDBSU	Parkinson disease	8A00.0	Phase 1	[3]
Posiphen R-phenserine	DMCU54M	Alzheimer disease	8A20	Phase 1	[6]
NPT200-11	DMFDBV5	Multiple system atrophy	8D87.0	Phase 1	[7]
Anle138b	DMEC8E2	Parkinson disease	8A00.0	Phase 1	[8]
UCB7853	DMD7I23	Parkinson disease	8A00.0	Phase 1	[9]

Drug(s) Targeting Insulin-like growth factor I receptor (IGF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teprotumumab	DM4L59B	Graves disease	5A02.0	Approved	[10]
Mecasermin	DM1O3BY	Growth failure	LD2F.1Y	Approved	[11]
Somatomedin-1	DMZ9FAO	Hormone deficiency	5A61.1	Approved	[12]
OSI-906	DMHKZLF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[13]
Rinfabate	DML9FD4	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[14]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[15]
TT-100	DMZE6Y9	Non-small-cell lung cancer	2C25.Y	Phase 2	[16]
AMG 479	DM0DRAZ	Breast cancer	2C60-2C65	Phase 2	[17]
VPI-2690B	DMUQZT4	Diabetic nephropathy	GB61.Z	Phase 2	[18]
AXL-1717	DMTQ1Y3	Solid tumour/cancer	2A00-2F9Z	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin-like growth factor I receptor (IGF1R)	TTHRID2	IGF1R_HUMAN	Not Available	[1]
Synuclein alpha (SNCA)	TT08OSU	SYUA_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Sanofi
• [2] alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012 February; 2(2): a009399.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.
• [5] Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019 Dec;132:104582.
• [6] The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5 ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13).
• [7] The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8(1):16165.
• [8] Anle138b interaction in alpha-synuclein aggregates by dynamic nuclear polarization NMR. Methods. 2023 Jun;214:18-27.
• [9] ClinicalTrials.gov (NCT04651153) A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease. U.S.National Institutes of Health.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
• [12] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [13] Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
• [14] Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
• [15] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [16] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [17] Clinical pipeline report, company report or official report of Amgen (2009).
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.